- Home
- EWTX vs VET Comparison
EWTX vs VET Comparison
Compare EWTX & VET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EWTX
- VET
- Stock Information
- Founded
- EWTX 2017
- VET 1994
- Country
- EWTX United States
- VET Canada
- Employees
- EWTX N/A
- VET N/A
- Industry
- EWTX Biotechnology: Pharmaceutical Preparations
- VET Oil & Gas Production
- Sector
- EWTX Health Care
- VET Energy
- Exchange
- EWTX Nasdaq
- VET Nasdaq
- Market Cap
- EWTX 1.2B
- VET 994.1M
- IPO Year
- EWTX 2021
- VET N/A
- Fundamental
- Price
- EWTX $14.58
- VET $6.41
- Analyst Decision
- EWTX Buy
- VET
- Analyst Count
- EWTX 8
- VET 0
- Target Price
- EWTX $40.13
- VET N/A
- AVG Volume (30 Days)
- EWTX 1.2M
- VET 1.3M
- Earning Date
- EWTX 05-08-2025
- VET 05-07-2025
- Dividend Yield
- EWTX N/A
- VET 5.47%
- EPS Growth
- EWTX N/A
- VET N/A
- EPS
- EWTX N/A
- VET N/A
- Revenue
- EWTX N/A
- VET $1,281,132,639.00
- Revenue This Year
- EWTX N/A
- VET $37.29
- Revenue Next Year
- EWTX N/A
- VET N/A
- P/E Ratio
- EWTX N/A
- VET N/A
- Revenue Growth
- EWTX N/A
- VET N/A
- 52 Week Low
- EWTX $10.60
- VET $5.14
- 52 Week High
- EWTX $38.12
- VET $12.68
- Technical
- Relative Strength Index (RSI)
- EWTX 41.67
- VET 47.39
- Support Level
- EWTX $13.82
- VET $5.90
- Resistance Level
- EWTX $17.30
- VET $6.33
- Average True Range (ATR)
- EWTX 1.02
- VET 0.26
- MACD
- EWTX 0.32
- VET 0.07
- Stochastic Oscillator
- EWTX 30.43
- VET 60.00
About EWTX Edgewise Therapeutics Inc.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.
About VET Vermilion Energy Inc. Common (Canada)
Vermilion Energy Inc is an international oil and gas-producing company. The company engages in full-cycle exploration and production programs that focus on the acquisition, exploration, development, and optimization of producing properties in North America, Europe, and Australia. The majority of Vermilion's revenue is derived from the production and sale of petroleum and natural gas. In each market, the company relies on a host of drilling and well-completion techniques to keep production at attractive levels. Geographically, the company derives majority of its revenue from Canada.